DSM-Firmenich Earnings: Sales Guidance Raised and Margin Path Intact; Shares Fairly Valued
DSM-Firmenich reported 5% third-quarter organic sales growth and raised its 2026 growth outlook to about 5% from 2%-4%. Adjusted EBITDA rose 8% on a like-for-like basis, with a 20.4% margin. Shares were flat intraday after opening about 7% lower on Nov. 4.